KHK2866

HB-EGF–targeting monoclonal antibody · Kyowa Kirin Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KHK2866, covering 2024-04-26 to 2024-04-26. Get the full timeline:

Most recent: Clinical Trial Update: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer [Phase 1]